Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FGFR Inhibition Overcomes Therapeutic Resistance and Immune Evasion in Oncogenic PIK3CA-Driven Serous Endometrial Cancers

ABSTRACT: We developed the first clinically relevant, immunocompetent SEC mouse model incorporating PIK3CA mutation, TP53 loss, and MYC overexpression. Through comprehensive analysis integrating mouse models, human cell lines, xenografts, and clinical samples, we investigated mechanisms of PIK3CA-targeted therapy resistance. Single-cell transcriptional profiling identified FGFR1/2 association with intrinsic resistance and FGFR3 with acquired resistance. Dual inhibition of FGFR and PI3Ka achieved enhanced tumor suppression. Additionally, we discovered that FGFR signaling promotes immune evasion by downregulating MHC-I/HLA-mediated antigen processing and presentation. Importantly, FGFR inhibition not only reversed immune suppression by restoring antigen presentation but also demonstrated a synergistic effect with anti-PD-1 therapy, enhancing immunotherapy response and anti-tumor immune memory. Our findings reveal FGFR's dual role in therapy resistance and immune evasion, supporting FGFR inhibition as a promising strategy to enhance treatment outcome in SEC patients.

ORGANISM(S): Mus musculus

PROVIDER: GSE311373 | GEO | 2026/02/24

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

FGFR Inhibition Overcomes Therapeutic Resistance and Immune Evasion in Oncogenic PIK3CA-Driven Serous Endometrial Cancers

Project description:We developed the first clinically relevant, immunocompetent SEC mouse model incorporating PIK3CA mutation, TP53 loss, and MYC overexpression. Through comprehensive analysis integrating mouse models, human cell lines, xenografts, and clinical samples, we investigated mechanisms of PIK3CA-targeted therapy resistance. Single-cell transcriptional profiling identified FGFR1/2 association with intrinsic resistance and FGFR3 with acquired resistance. Dual inhibition of FGFR and PI3Ka achieved enhanced tumor suppression. Additionally, we discovered that FGFR signaling promotes immune evasion by downregulating MHC-I/HLA-mediated antigen processing and presentation. Importantly, FGFR inhibition not only reversed immune suppression by restoring antigen presentation but also demonstrated a synergistic effect with anti-PD-1 therapy, enhancing immunotherapy response and anti-tumor immune memory. Our findings reveal FGFR's dual role in therapy resistance and immune evasion, supporting FGFR inhibition as a promising strategy to enhance treatment outcome in SEC patients.

2026-02-24 | GSE292814 | GEO

FGFR Inhibition Overcomes Therapeutic Resistance and Immune Evasion in Oncogenic PIK3CA-Driven Serous Endometrial Cancers

Project description:FGFR Inhibition Overcomes Therapeutic Resistance and Immune Evasion in Oncogenic PIK3CA-Driven Serous Endometrial Cancers

| PRJNA1241295 | ENA

FGFR Inhibition Overcomes Therapeutic Resistance and Immune Evasion in Oncogenic PIK3CA-Driven Serous Endometrial Cancers

Project description:FGFR Inhibition Overcomes Therapeutic Resistance and Immune Evasion in Oncogenic PIK3CA-Driven Serous Endometrial Cancers

| PRJNA1369365 | ENA

Mogat1 drives metabolic adaptations to evade immune surveillance

Project description:Despite immune checkpoint blockades have achieved remarkable success, most patients with solid tumors do not respond or develop resistance, suggesting additional treatment strategies are needed. Concentrated efforts are directed toward revitalizing the IFNγ pathway or amplifying antigen presentation capabilities, alternative mechanisms underlying immune evasion remain poorly understood. Using an unbiased whole-genome in vivo natural selection screen, we identified an uncharacterized role of Monoacylglycerol O-Acyltransferase 1 (Mogat1) as a critical modulator of tumor immune evasion. As tumors progress and expand, they undergo systemic metabolic adaptations to evade immune surveillance. Tumor cells exploit Mogat1 to sequester excess fatty acids into triglycerides, orchestrating metabolic reprogramming that simultaneously fuels tumor growth and creates an immunosuppressive microenvironment. Mogat1 inhibition suppresses tumor growth by promoting T-cell infiltration and cytotoxicity. Remarkably, Mogat1 loss facilitates the circumvention of PD-1 checkpoint blockade resistance. This heightened inflammatory response, characterized by increased interferon sensitivity, circumvents the need for conventional antigen presentation. Our findings reveal a novel lipid metabolism-centered mechanism of immune evasion and offer a potential strategy to enhance cancer immunotherapy efficacy.

2024-08-16 | GSE274902 | GEO

Targeting β-catenin overcomes resistance to MEK inhibitor in PIK3CA mutant colon cancer

Project description:Mitogen-activated protein kinases (MEK 1/2) are central components of the RAS signaling pathway and attractive targets for cancer therapy. However, PIK3CA mutation, which commonly co-occurs with KRAS mutation, offered resistance to MEK inhibitor through activation of PI3K-AKT signaling. We identified a gene that cooperates with MEK inhibitors to forcefully treat PIK3CA mutant colon cancer cells. -catenin, a key molecule of the WNT pathway, emerged as a candidate by protein/Ab Chip array. MEK inhibitor treatment led to a decrease in -catenin in PIK3CA wild-type colon cancer cells but not in PIK3CA mutant colon cancer cells. Tumor regression was promoted by a combination of MEK inhibitor and NVP-TNS656, which targets the WNT pathway. Furthermore, combined inhibition of MEK and -catenin by NVP-TNS656 promoted tumor regression in colon cancer patient-derived xenograft (PDX) models expressing mutant PIK3CA. Taken together, we propose that inhibition of the WNT pathway, particularly -catenin, may bypass resistance to MEK inhibitor in human PIK3CA mutant colon cancer. Additionally, -catenin is a potential PD marker of MEK inhibitor resistance. In the study, we identified and evaluated biomarker for response to MEK inhibitor on colon cancer cells.

2015-08-13 | E-GEOD-71981 | biostudies-arrayexpress

Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer [ChIP_seq]

Project description:A subset of triple negative breast cancers (TNBC) are characterized by genetic alterations in fibroblast growth factor receptors (FGFR) including amplifications, activating mutations or gene fusions. However, despite this genetic evidence of FGFR-dependency, FGFR inhibitors have shown only limited clinical efficacy in TNBC, suggesting the presence of intrinsic or adaptive resistance mechanisms. Using genome-wide CRISPR screens, we found that resistance to FGFR inhibition is mediated by activation of the mTORC1 and YAP pathways. Prolonged FGFR inhibition increased expression of several amino acid transporters resulting in increased cellular level of certain amino acids and activation of the mTORC1 amino acid sensing pathway. Epigenomic analyses revealed that FGFR inhibition reorganized YAP/TEAD associated enhancers leading to the upregulation of YAP target genes including the amino acid transporters upstream of mTORC1. Remarkably, mTORC1 and FGFR inhibitors synergistically blocked the growth of TNBC cells in vitro and in patient-derived xenografts. These findings define a novel epigenetic feedback mechanism involving intracellular amino acid levels leading to targeted therapy resistance in TNBC, and offers a combinatorial drug treatment strategy to improve clinical outcomes for this aggressive breast cancer subtype.

2021-09-09 | GSE168024 | GEO

Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer [RNA_seq]

2021-09-09 | GSE168023 | GEO